問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Far Eastern Memorial Hospital (在職)

Division of Nephrology

更新時間：2023-09-19

吳泓彥
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

26Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

吳泓彥

List

33Cases

2024-02-01 - 2028-12-31

Phase III

Active
A Phase III, Randomised, Double-blind Study to Assess the Efficacy, Safety, and Tolerability of Baxdrostat in Combination with Dapagliflozin Compared with Dapagliflozin Alone on Chronic Kidney Disease (CKD) Progression in Participants with CKD and High Blood Pressure

  • Condition/Disease

    Chronic Kidney Disease and Hypertension

  • Test Drug

    Baxdrostat Dapagliflozin

Participate Sites
11Sites

Not yet recruiting5Sites

Recruiting6Sites

2023-12-28 - 2027-02-28

Phase III

A Phase III, Randomized, Investigator-Blinded, Active-Controlled Study of Efficacy and Safety of Efepoetin Alfa for Treatment of Anemia in Patients with Chronic Kidney Disease on Dialysis

  • Condition/Disease

    Chronic Kidney Disease on Dialysis

  • Test Drug

    Efepoetin alfa (GX-E4)

Participate Sites
5Sites

Recruiting5Sites

2019-01-01 - 2023-06-30

Phase III

A Phase 3 Study of PBF-1681 Comprising a 16-week, Placebo-controlled, Double-blind Randomized Period and an 8-week, Open-label Extension Period for the Treatment of Iron Deficiency Anemia in Patients With Non-Dialysis Dependent CKD

  • Condition/Disease

    Iron Deficiency Anemia With Non-Dialysis Dependent CKD

  • Test Drug

    PBF-1681

Participate Sites
12Sites

Recruiting1Sites

Terminated11Sites

2017-01-01 - 2018-12-31

Phase IV

A Long-Term, Open-Label, Prospective Observational Phase IV Study to Assess the Safety and Efficacy of Nephoxil® in Subjects with End Stage Renal Disease (ESRD) on Dialysis.

  • Condition/Disease

    Hyperphosphatemia/End Stage Renal Disease (ESRD)

  • Test Drug

    NEPHOXIL®

Participate Sites
9Sites

Terminated9Sites

2015-01-01 - 2017-12-31

Phase III

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Roxadustat for the Treatment of Anemia in Chronic Kidney Disease Patients not on Dialysis

  • Condition/Disease

    Chronic Kidney Disease

  • Test Drug

    Roxadustat

Participate Sites
12Sites

Study ended12Sites

洪振傑
Linkou Chang Gung Medical Foundation

Division of Nephrology

唐德成
Taipei Veterans General Hospital

Division of Nephrology

2015-01-01 - 2020-06-30

Phase III

A phase 3 multicenter, prospective, randomized, double-blind, placebo controlled study to investigate the safety and efficacy of ZS (sodium zirconium cyclosilicate), in patients with hyperkalemia - HARMONIZE Global

  • Condition/Disease

    Hyperkalemia

  • Test Drug

    ZS

Participate Sites
7Sites

Terminated7Sites

2016-12-01 - 2021-11-30

Phase III

A phase 3 randomized, open-label (sponsor-blind), active-controlled, parallel-group, multi-center, event driven study in non-dialysis subjects with anemia associated with chronic kidney disease to evaluate the safety and efficacy of daprodustat compared to darbepoetin alfa

  • Condition/Disease

    non-dialysis with anemia associated with chronic kidney disease

  • Test Drug

    Daprodustat (GSK1278863)

Participate Sites
12Sites

Recruiting7Sites

Terminated5Sites

蘇裕謀
Taipei WanFang Hospital (Managed by Taipei Medical Univeristy)

Division of Nephrology

2016-12-01 - 2020-12-31

Phase III

ASCEND-D: A phase 3 randomized, open-label (sponsor-blind), active-controlled, parallel-group, multi-center, event driven study in dialysis subjects with anemia associated with chronic kidney disease to evaluate the safety and efficacy of daprodustat compared to recombinant human erythropoietin, following a switch from erythropoietin-stimulating agents

  • Condition/Disease

    dialysis subjects with anemia associated with chronic kidney disease

  • Test Drug

    Daprodustat (GSK1278863)

Participate Sites
12Sites

Terminated12Sites

2023-06-30 - 2030-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2020-11-19 - 2024-12-31

Phase III

A Phase 3b, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of TRC101 in Delaying Chronic Kidney Disease Progression in Subjects With Metabolic Acidosis

  • Condition/Disease

    Chronic Kidney Disease With Metabolic Acidosis

  • Test Drug

    TRC101

Participate Sites
12Sites

Recruiting11Sites

Terminated1Sites

1 2 3 4
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB